• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Bedaquiline-linezolid regimen noninferior to standard treatment for tuberculosis

byBryant LimandKiera Liblik
March 17, 2023
in Chronic Disease, Infectious Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this randomized control trial, an eight-week bedaquiline-linezolid regimen was noninferior to standard 24-week treatment for tuberculosis.

2. The incidence of serious adverse events was not significantly different between the bedaquiline-linezolid regimen and standard treatment.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The current standard of treatment for tuberculosis is a six-month rifampin-based regimen. While it is effective in clinical trials, difficulty with long-term treatment adherence has led to reduced efficacy in real-world program implementation. In addition, at least 85% of clinical trial participants are cured within three to four months of treatment. The entire six-month regimen may lead to overtreatment in most patients. In this noninferiority open-label randomized control trial, initial therapy with two eight-week regimens followed by extended treatment for persistent clinical disease, monitoring after treatment, or retreatment for relapse was compared with a standard 24-week regimen for adult patients with tuberculosis. The two eight-week regimens were rifampin-linezolid or bedaquiline-linezolid combined with isoniazid, pyrazinamide, and ethambutol. Patients were followed for 96 weeks. For the primary outcome, a composite of death or ongoing tuberculosis treatment or active tuberculosis by week 96, the noninferiority criterion was met for the group with an initial bedquiline-linezolid regimen and not for the group with an initial rifampin-linezolid regimen. The shorter duration regimens also had a positive effect on participant motivation to adhere to treatment. As a limitation, this was an open-label design, which may introduce treatment bias.

Click to read the study in NEJM

Relevant Reading: Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis

In-Depth [randomized controlled trial]: In this noninferiority, open-label, randomized controlled trial, adult patients (n = 675) with nucleic acid amplification test or radiograph-confirmed tuberculosis were randomized to receive one of four eight-week initial treatment regimens [rifampin-linezolid (n=184); bedaquiline-linezolid (n=189); rifapentine-linezolid (n=78); rifampin-clofazimine (n = 42)] or standard treatment (n=181). The rifapentine-linezolid and rifampin-clofazimine groups did not achieve complete enrollment. For the eight-week initial regimens, treatment was continued for persistent or relapse of clinical disease. Patients were followed for 96 weeks. For the primary outcome, a composite of death, ongoing treatment, or active disease at 96 weeks, the noninferiority criterion compared to the standard treatment (3.9%) was not met in the rifampin-linezolid group (11.4% adjusted difference; 7.4 percentage points; 97.5% Confidence Interval [CI], 1.7 to 3.2) and met in the bedquiline-linezolid group (5.8% adjusted difference; 0.8 percentage points; 97.5% CI -3.4 to 5.1). For the patient-centered secondary outcomes, the mean total duration of treatment was 180, 106, and 85 days for the standard, rifampin-linezolid, and bedaquiline-linezolid groups, respectively. Participants in the eight-week initial treatment groups reported lower anxiety related to the regimen and higher motivation to take treatment. Incidences of respiratory disability, serious adverse events, and death at the end of the study were not significantly different between groups. This study suggests that there may be value in shifting the tuberculosis management strategy from a 24-week regimen to a shorter regimen.

RELATED REPORTS

Mycobacterium abscessus infections after cardiac surgery linked to hospital water system

#VisualAbstract: Bedaquiline-linezolid regimen noninferior to standard treatment for tuberculosis

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antituberculosis treatmentBedaquilineBedaquiline-linezolidchronic diseaseinfectious diseaselinezolidmycobacterium tuberculosispulmonologyrespirologytuberculosis
Previous Post

Prior COVID-19 infection may result in poorer sleep health

Next Post

Pituitary microadenomas exhibit slow growth and may require less frequent MRI surveillance

RelatedReports

Standardized central line care practices reduce bloodstream infections
Infectious Disease

Mycobacterium abscessus infections after cardiac surgery linked to hospital water system

March 23, 2023
Auto Draft
StudyGraphics

#VisualAbstract: Bedaquiline-linezolid regimen noninferior to standard treatment for tuberculosis

March 23, 2023
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

March 21, 2023
Oral amoxicillin as effective as injectable benzylpenicillin-gentamicin for infants with infection in which referral not possible [AFRINEST Trial]
Infectious Disease

Combination doxycycline and azithromycin therapy effective in treating severe scrub typhus

March 20, 2023
Next Post
Proton radiotherapy may be effective for refractory pituitary adenomas

Pituitary microadenomas exhibit slow growth and may require less frequent MRI surveillance

#VisualAbstract: Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer

#VisualAbstract: Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer

#VisualAbstract: Routine invasive strategy not associated with improved outcomes in older adults with frailty and non-ST segment elevation acute myocardial infarction

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stroke may be associated with sleep disturbances in adults
  • Transcarotid artery revascularization not associated with a significant difference in 30-day risk of stroke, death and myocardial infarction compared to carotid endarterectomy
  • Drinking characteristics in adolescence predict alcohol behaviors in early adulthood
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options